

Ocular Hypertension Treatment Study (OHTS)

Current as of: 05/01/18

<https://ohts.wustl.edu>

1. Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group: [The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants](#). Arch Ophthalmol 1999; 117:573-83. [PMID: 10326953](#).
2. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. [Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2000; 118:1187-94. [PMID: 10980763](#). [View PowerPoint Presentation](#).
3. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. [Contralateral Effect of Topical \$\beta\$ -Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2000; 130:441-53. [PMID: 11024416](#).
4. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Central Corneal Thickness in the Ocular Hypertension Treatment Study \(OHTS\)](#). Ophthalmology 2001; 108:1779-88. [PMID: 11581049](#). [View PowerPoint Presentation](#).
5. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Reproducibility of Cup/Disk Ratio Measurements Over Time at an Optic Disc Reading Center](#). Am J Ophthalmol 2002; 133:19-28. [PMID: 11755836](#).
6. Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Study Group. [Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study](#). Ophthalmology 2002; 109:432-7. [PMID: 11874743](#).
7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma](#). Arch Ophthalmol 2002; 120:701-13. [PMID: 12049574](#). [View PowerPoint Presentation](#). [\[Editorial\]](#).
8. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma](#). Arch Ophthalmol 2002; 120:714-20. [PMID: 12049575](#).
9. Palmberg P. [Answers From the Ocular Hypertension Treatment Study](#). Arch Ophthalmol. 2002 Jun;120(6):829-30. [PMID: 1204959](#).

10. Lee BL, Wilson MR; Ocular Hypertension Treatment Study (OHTS). [Ocular Hypertension Treatment Study \(OHTS\) commentary](#). Curr Opin Ophthalmol. 2003 Apr;14(2):74-7. PMID: [12698045](#).
11. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. [Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2003; 121:643-50. PMID: [12742841](#).
12. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA, for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. [Racial Differences in Optic Disc Topography: Baseline Results From the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2004; 122:22-8. PMID: [14718290](#).
13. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA and the OHTS CSLO Ancillary Study Group. [The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study Design and Baseline Factors](#). Am J Ophthalmol 2004; 137:219-27. PMID: [14962409](#). [View PowerPoint Presentation](#).
14. Robin AL, Frick KD, Katz J, Budenz D, Tielsch JM. [The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?](#) Arch Ophthalmol. 2004 Mar;122(3):376-8. Review. Erratum in: Arch Ophthalmol. 2004 Jul;122(7):1039. PMID: [15006854](#).
15. Jampel HD. [We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study](#). Arch Ophthalmol. 2004 Mar;122(3):378-9. PMID: [15006855](#).
16. Brandt JD. [Corneal Thickness in Glaucoma Screening, Diagnosis, and Management](#). Curr Opin Ophthalmol. 2004 Apr;15(2):85-9. PMID: [15021216](#).
17. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals](#). Arch Ophthalmol 2004; 122:813-20. PMID: [15197055](#). [View PowerPoint Presentation](#).
18. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study (OHTS). [Baseline Risk Factors for the Development of Primary Open-angle Glaucoma in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2004; 138(4):684-5. PMID: [15488816](#).

19. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2004; 138:717-22. [PMID: 15531304](#).
20. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS) Group. [Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice. Letter to Editor](#). Arch Ophthalmol 2005; 123:1021-2. [PMID: 16009857](#).
21. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. [Baseline Topographic Optic Disc Measurements are Associated With the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2005; 123:1188-97. [PMID: 16157798](#). [View PowerPoint Presentation](#).
22. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group. [Normal Visual Field Test Results Following Glaucomatous Visual Field End Points in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2005; 123:1201-6. [PMID: 16157799](#). [PMCID: PMC1828122](#).
23. Medeiros FA, Weinreb RN, Sample PA, Gomi CF, Bowd C, Crowston JG, Zangwill LM. [Validation of a Predictive Model to Estimate the Risk of Conversion From Ocular Hypertension to Glaucoma](#). Arch Ophthalmol. 2005 Oct;123(10):1351-60. [PMID: 16219726](#).
24. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke R, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. [Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders](#). Am J Ophthalmol 2005; 140:762-4. [PMID: 16226544](#). [View PowerPoint Presentation](#).
25. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group (OHTS). [Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2006; 141:997-1008. [PMID: 16765666](#). [PMCID: PMC1775049](#).
26. Higginbotham EJ. [Treating Ocular Hypertension to Reduce Glaucoma Risk: When to Treat?](#) Drugs. 2006;66(8):1033-9. [PMID: 16789790](#).
27. Herman DC, Hodge DO, Bourne, WM. [Changes in the Corneal Thickness in Patients With Treated and Untreated Ocular Hypertension](#). Cornea 2006; 25:639-43. [PMID: 17077653](#).
28. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study Group. [Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study](#). Invest Ophthalmol Vis Sci 2006; 47:3896-903. [PMID: 16936102](#). [PMCID: PMC1995656](#).

29. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, Ocular Hypertension Treatment Study Group. [The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the Ocular Hypertension Treatment Study](#). Ophthalmology 2006; 113(9):1603-12. [PMID: 16949445](#). [PMCID: PMC1995656](#).
30. Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, Bourne WM. [Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves Among Participants in the Ocular Hypertension Treatment Study](#). Cornea 2006; 25:1046-52. [PMID:17133051](#).
31. Mansberger SL, Cioffi GA. [The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator](#). J Glaucoma. 2006 Oct;15(5):426-31. [PMID: 16988606](#).
32. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group. [Topical Ocular Hypotensive Medication and Lens Opacification: Evidence From the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2006; 142:800-10. [PMID: 17056362](#). [PMCID: PMC1976472](#). [View PowerPoint Presentation](#).
33. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. [Detection and Prognostic Significance of Optic Disc Hemorrhages During the Ocular Hypertension Treatment Study](#). Ophthalmology 2006; 113(12):2137-43. [PMID: 16996592](#). [PMCID: PMC1995568](#). [View PowerPoint Presentation](#).
34. Ocular Hypertension Treatment Study (OHTS) Group, European Glaucoma Prevention Study Group. [Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension](#). Ophthalmology 2007; 114(1):10-9. [PMID: 17095090](#). [PMCID: PMC1995665](#). [View PowerPoint Presentation](#).
35. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Comparison of Initial Intraocular Pressure Response With Topical \$\beta\$ -Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study](#). Archives of Ophthalmology 2007; 125(4):454-9. [PMID: 17420364](#).
36. Brandt JD. [Central Corneal Thickness, Tonometry, and Glaucoma Risk--A Guide for the Perplexed](#). Can J Ophthalmol. 2007 Aug;42(4):562-6. [PMID: 17641698](#).
37. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. [Visual Field Quality Control in the Ocular Hypertension Treatment Study \(OHTS\)](#). J Glaucoma 2007; 16:665-9. [PMID: 18091452](#).

38. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. [Is a History of Diabetes Mellitus Protective Against Developing Primary Open-angle Glaucoma?](#) Arch Ophthalmol 2008; 126:280-2. [PMID: 18268230](#). [View PowerPoint Presentation](#).
39. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. [Diabetes and Glaucoma](#). Arch Ophthalmol 2008;126(5):746-a-7. [PMID: 18474807](#).
40. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA, Ocular Hypertension Treatment Study Group. [Changes in Central Corneal Thickness over Time: The Ocular Hypertension Treatment Study](#). Ophthalmology 2008; 115:1550-6. [PMID: 18378313](#).
41. The Ocular Hypertension Treatment Group and the European Glaucoma Prevention Study Group. [The Accuracy and Clinical Application of Predictive Models for Primary Open-Angle Glaucoma in Ocular Hypertensive Individuals](#). Ophthalmology 2008; 115(11):2030-6. [PMID: 18801578](#). [PMCID: PMC3117658](#).
42. Boland MV, Quigley HA, Lehmann HP. [The Impact of Risk Calculation on Treatment Recommendations Made by Glaucoma Specialists in Cases of Ocular Hypertension](#). J Glaucoma. 2008 Dec;17(8):631-8. [PMID: 19092458](#).
43. Higginbotham EJ. [Ocular Hypertension Treatment Study](#). Arch Ophthalmol. 2009 Feb;127(2):213-5. [PMID: 19204243](#).
44. Bhorade AM, Gordon MO, Wilson B, Weinreb RN, Kass MA, for the Ocular Hypertension Treatment Study Group. [Variability of Intraocular Pressure Measurements in Observation Participants in the Ocular Hypertension Treatment Study](#). Ophthalmology 2009;116:717-24. [PMID: 19243824](#). [PMCID: PMC2790916](#). [View PowerPoint Presentation](#).
45. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, for the Ocular Hypertension Treatment Study Group. [Delaying Treatment of Ocular Hypertension](#). Arch Ophthalmol 2010;128(3):276-87. [PMID: 20212196](#). [PMCID: PMC3966140](#). [View PowerPoint Presentation](#).
46. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. [The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study](#). Ophthalmology 2010;117(3):484-8. [PMID: 20031222](#). [PMCID: PMC3077045](#).
47. Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO. [Effect of Patient's Life Expectancy on the Cost-effectiveness of Treatment for Ocular Hypertension](#). Arch Ophthalmol 2010;128(5):613-8. [PMID: 20457984](#). [PMCID: PMC4010144](#).
48. Weinreb RN, Zangwill LM, Jain Sonia, Becerra LM, Dirkes Keri, Piltz-Seymour JR, Cioffi GA, Trick GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA, for the OHTS CSLO Ancillary Study Group. [Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Ophthalmology 2010;117(9):1674-83. [PMID: 20633931](#). [PMCID: PMC3938159](#).

49. Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA, for the Ocular Hypertension Treatment Study Group. [The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2010;117(11):2047-54. [PMID: 20619460](#). [PMCID: PMC2955184](#).
50. Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Group. [Longitudinal and Cross-sectional Analyses of Visual Field Progression in Participants of the Ocular Hypertension Treatment Study](#). *Arch Ophthalmol* 2010;128(12):1528-32. [PMID: 21149774](#). [PMCID: PMC3914151](#).
51. Gao F, Miller JP, Xiong C, Beiser JA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. [A Joint-modeling Approach to Assess the Impact of Biomarker Variability on the Risk of Developing Clinical Outcome](#). *Statistical Methods & Applications* 2011;20(1):83-100. [PMID: 21339862](#). [PMCID: PMC3039885](#).
52. Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA. [A joint Model for Prognostic Effect of Biomarker Variability on Outcomes: Long-term Intraocular Pressure \(IOP\) Fluctuation on the Risk of Developing Primary Open-Angle Glaucoma \(POAG\)](#). *JP Journal of Biostatistics* 2011 May 1;5(2) 73-96. [PMID: 22180704](#). [PMCID: PMC3237682](#).
53. Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA. [The 10-Year Incidence of Glaucoma Among Patients With Treated and Untreated Ocular Hypertensive](#). *Arch Ophthalmol* 2011;129(12):1630-1. [PMID: 22159688](#).
54. Demirel S, De Moraes CG, Gardiner SK, Liebmann JM, Cioffi GA, George R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study. [The Rate of Visual Field Change in the Ocular Hypertension Treatment Study](#). *Invest Ophthalmol Vis Sci* 2012;53(1)224-7. [PMID: 22159015](#). [PMCID: PMC3292359](#).
55. Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA, for the Ocular Hypertension Treatment Study Group. [Adjusting Intraocular Pressure for Central Corneal Thickness Does Not Improve Prediction Models for Primary Open-Angle Glaucoma](#). *Ophthalmology* 2012;119(3):437-42. [PMID: 21705084](#). [PMCID: PMC3184359](#).
56. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Effect of Treatment on the Rate of Visual Field Change in the Ocular Hypertension Treatment Study Observation Group](#). *Invest Ophthalmol Vis Sci* 2012;53:1704-9. [PMID: 22395889](#). [PMCID: PMC3342789](#).
57. Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO. [The Development of a Decision Analytic Model of Changes in Mean Deviation in People with Glaucoma](#). *Ophthalmology* 2012;119:1367-74. [PMID: 22537616](#). [PMCID: PMC3389134](#).

58. Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA, for the Ocular Hypertension Treatment Study Group. [Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment Study](#). *Ophthalmology* 2012;119:1826-31. [PMID: 22608478](#). [PMCID: PMC3426647](#).
59. Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA, Gordon MO. [The Effect of Changes in Intraocular Pressure on the Risk of Primary Open-angle Glaucoma in Patients with Ocular Hypertension: An Application of Latent Class Analysis](#). *BMC Med Res Methodol*. 2012 Oct 4;12:151. [PMID: 23035867](#). [PMCID: PMC3532135](#).
60. De Moraes CG, Demirel S, BScOptom, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study](#). *Arch Ophthalmol* 2012;130:1541-46. [PMID: 22892940](#).
61. Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi, GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Series Length used during Trend Analysis Affects Sensitivity to Changes in Progression Rate in the Ocular Hypertension Treatment Study \(OHTS\)](#). *Invest Ophthalmol Vis Sci*. 2013;54(2): 1252–9. [PMID 23349433](#). [PMCID: PMC3597197](#).
62. Gardiner SK, Demirel S, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Seasonal Changes in Visual Field Sensitivity and Intraocular Pressure in the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2013 Apr;120(4):724-30. [PMID: 23357622](#). [PMCID: PMC3618610](#).
63. Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN; Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. [The Rate of Structural Change: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). *Am J Ophthalmology* 2013;155(6):971–82. [PMID: 23497845](#). [PMCID: PMC4310682](#).
64. Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR; Ocular Hypertension Treatment Study [Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment](#). *Ophthalmology* 2015 Jan;122(1):79-86. [PMID: 25208858](#). [PMCID: PMC4682350](#).
65. Christopher M, Abramoff MD, Tang L, Gordon MO, Kass MA, Budenz DL, Fingert JH, Scheetz TE. [Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension](#). *Invest Ophthalmol Vis Sci*. 2015 Jul 1;56(8):4470-9. [PMID: 26193923](#). [PMCID: PMC4509059](#).
66. Feng Gao, J Philip Miller, Julia A Beiser, Chengjie Xiong, Mae O Gordon. [Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma](#). *J Biom Biostat* 6:254. [PMID: 26904374](#). [PMCID: PMC4760987](#).

67. Schaefer JL, Lukowski ZL, Meyer AM, Leoncavallo AJ, Greer A, Martorana GM, Zou B, Shuster JJ, Sherwood MB. [Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Software Program in Ophthalmologists-in-Training](#). *Am J Ophthalmol*. 2016 Jul;167:88-95. [PMID: 27038890](#). [PMCID: PMC5697426](#).
68. Scheetz TE, Faga B, Ortega L, et al. [Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2016;123(12):2527-36. [PMID: 27707548](#). [PMCID: PMC5121091](#).
69. Khawaja AP, Cooke Bailey JN, et al. [Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses](#). *Invest Ophthalmol Vis Sci*. 2016 Sep; 57(11): 5046–5052. [PMID: 27661856](#). [PMCID: PMC5040191](#).
70. Bailey JN, Loomis SJ, et al. [Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open angle glaucoma](#). *Nat Genet*. 2016 Feb; 48(2): 189–194. [PMID: 26752265](#). [PMCID: PMC4731307](#).
71. Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M, Ocular Hypertension Treatment Study. [Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study](#). *Am J Ophthalmol*. Feb 2017;174:126-133. [PMID: 27832941](#). [PMCID: PMC5658027](#).
72. Jamie L Schaefer, Alissa M Meyer, Cooper D Rodgers, Nicole C Rosenberg, Anthony J Leoncavallo, Zachary L Lukowski, Anthony B Greer, Gina M Martorana, Baiming Zou, Jonathan J Shuster, L Jay Katz, Joel S Schuman, Michael A Kass, Mark B Sherwood. [Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Programme in Glaucoma Experts and Trainees](#). *Br J Ophthalmol*. 2018 Mar;102(3):358-363. [PMID: 28814418](#).
73. Gao F, Philip Miller J, Xiong C, Luo J, Beiser JA, Chen L, Gordon MO. [Estimating Correlation Between Multivariate Longitudinal Data in the Presence of Heterogeneity](#). *BMC Med Res Methodol*. 2017 Aug 17;17(1):124. [PMID: 28818061](#). [PMCID: PMC5561646](#).
74. Chen Z, Wang K. [A Gene-based Test of Association Through an Orthogonal Decomposition of Genotype Scores](#). *Hum Genet*. 2017 Oct;136(10):1385-1394. [PMID: 28864915](#).
75. Wang K. [Conditional Asymptotic Inference for the Kernel Association Test](#). *Bioinformatics*. 2017 Dec 1;33(23):3733-3739. [PMID: 28961861](#). [PMCID: PMC5860324](#).
76. Gordon MO, Kass MA. [What We Have Learned From the Ocular Hypertension Treatment Study](#). *Am J Ophthalmol*. 2018 May;189:xxiv-xxvii. [PMID: 29501371](#). [PMCID: PMC5915899](#).